PriceTargets.com logo

Grail - GRAL Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$15.09 As of 11/20/2024 01:00 AM ET
▲ +0.3 (2.03%)

This chart shows the closing price for GRAL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Grail Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GRAL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GRAL

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Grail in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $15.09.

This chart shows the closing price for GRAL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 2 contributing investment analysts is to hold stock in Grail.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/15/2024Wolfe ResearchInitiated CoveragePeer Perform
10/17/2024GuggenheimInitiated CoverageNeutral
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.21 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 2 very positive mentions
  • 42 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 3 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 3 very negative mentions
Mentions as of
9/21/2024
  • 8 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
10/21/2024
  • 2 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 2 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Grail logo
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
Read More

Today's Range

Now: $15.09
Low: $14.68
High: $15.48

50 Day Range

MA: $13.87
Low: $12.57
High: $15.92

52 Week Range

Now: $15.09
Low: $12.33
High: $23.36

Volume

481,166 shs

Average Volume

1,085,086 shs

Market Capitalization

$507.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Grail?

The following Wall Street analysts have issued stock ratings on Grail in the last twelve months: Guggenheim, and Wolfe Research.
View the latest analyst ratings for GRAL.

What is the current price target for Grail?

0 Wall Street analysts have set twelve-month price targets for Grail in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Grail in the next year.
View the latest price targets for GRAL.

What is the current consensus analyst rating for Grail?

Grail currently has 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GRAL, but not buy more shares or sell existing shares.
View the latest ratings for GRAL.

What other companies compete with Grail?

Other companies that are similar to Grail include GeneDx, National HealthCare, Fortrea, Viridian Therapeutics and Teladoc Health. Learn More about companies similar to Grail.

How do I contact Grail's investor relations team?

Grail's physical mailing address is 1525 O'brien DRIVE, MENLO PARK, CA, 94025. The company's listed phone number is (650) 771-9796 and its investor relations email address is [email protected]. The official website for Grail is grail.com. Learn More about contacing Grail investor relations.